Erasca - ERAS Operating profit EBITDA
Global conflicts and sanctions are hindering international drug trials, creating logistical barriers for Erasca, Inc. (ERAS). The company is overcoming this through partnerships with medical centers and the acquisition of biotech startups. Experienced management is effectively controlling R&D expenses. The EBITDA trajectory confirms financial stability, where the current parameter equals 0.00, demonstrating the ability to act as a cash generator.
Summary analytical data breakdowns for Erasca (ERAS)
- current quotes and average value forecast:
- issuer market value details:
- book value of equity indicators:
- debt level and financial liquidity data:
- earnings and market ratios statistics:
ERAS - Net Profit|Projected Future Earnings Erasca, Inc.|ERAS - Price to Earnings Ratio|Future Price to Earnings Multiple erasca.com|ERAS - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Erasca|ERAS - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Erasca|ERAS - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months erasca.com|ERAS - Net earnings per share growth this year|Consensus forecast of earnings per share growth for next year Erasca, Inc.
Summary company analytics:ERAS (Erasca Oncology)
Assessing investment risks requires an analysis of liquidity from sales before taxes and depreciation, which allows for the determination of cash flow stability through the volume of the operating cash result. For Erasca, Inc. (ERAS), which is developing precision oncology, this indicator visualizes the company's ability to fund innovative therapies against RAS/MAPK mutations, although a steady growth curve does not eliminate the need to account for total debt.
Competitors of Erasca, Inc. (ERAS)
ONC - Operating profit before deduction of amortization|HALO: Operating profit before deduction of amortization|RVMD - Operating profit EBITDA|Ascentage Pharma (AAPG) - Profit before payment of interest, taxes and amortization|CG Oncology Inc - Income before deduction of interest, taxes and amortization|URGN (UroGen) - Operating profit EBITDA|Profit before interest, taxes and amortization Bicara Corp BCAX|Operating profit EBITDA PSNL|DCTH - Profit before interest, taxes and amortization|Profit before payment of interest, taxes and amortization Y-mAbs Therapeutics, Inc. YMAB|Income before deduction of interest, taxes and amortization AURA|Candel - Operating profit EBITDA|ARAY - Operating profit EBITDA|sellaslifesciences.com (SLS) - Profit before payment of interest, taxes and amortization|ACTU - Operating income before deduction of amortization|CTOR (Citius Oncology) - Operating profit EBITDA|Operating profit before deduction of amortization TuHURA (HURA)|Operating profit EBITDA TARA|Operating profit EBITDA Fate Pharma (FATE)|Aadi Bioscience - Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization TCRX|Champions Oncology Corp - Operating profit EBITDA|Operating income before deduction of amortization XBiotech Inc. XBIT|cel-sci.com (CVM) - Profit before payment of interest, taxes and amortization|Operating profit before amortization OSTX|RADX (Radiopharm Theranostics) - Operating profit EBITDA|Operating profit before deduction of amortization Artiva (ARTV)|Operating profit before deduction of amortization ANL (Adlai Nortye Ltd.)|Operating income before deduction of amortization Veru Inc|Operating profit EBITDA TPST (Tempest Tx)|Xilio Therapeutics Inc (XLO) - Profit before interest, taxes and amortization|RENB - Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization MURA (Mural Oncology plc)|KAPA: Operating profit EBITDA|OnKure Therapeutics (OKUR) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization CytoMed Therapeutics Ltd|Curis Corp (CRIS) - Operating income before deduction of amortization|Operating profit EBITDA APLM|Operating profit before deduction of amortization tharimmune.com THAR|Operating profit EBITDA ADVB (Advanced Biomed)|Operating profit EBITDA Genprex Inc. GNPX|CLDI - Profit before payment of interest, taxes and amortization|SBFM (sunshinebiopharma.com) - Operating profit before amortization|XBIO: Operating profit EBITDA|Operating profit before deduction of amortization salariuspharma.com|PPBT (Purple Biotech Ltd.) - Operating profit EBITDA|Profit before interest, taxes and amortization AON AONC|Profit before payment of interest, taxes and amortization BeOne Medicines (BGNE)|CKPT (Checkpoint Therapeutics Inc) - Income before deduction of interest, taxes and amortization|Elevation Oncology - Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization ICAD|Ikena - Operating profit EBITDA|Notable Labs Ltd (NTBL) - Operating profit before deduction of amortization|VIRX (viracta.com) - Operating profit before deduction of amortization|MorphoSys Corporation (MOR) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization NAYA Biosciences|AAPGV: Income before deduction of interest, taxes and amortization
